kidney development

Dapagliflozin ((2S)-1,2-propanediol, hydrate) (BMS-512148 (2S)-1,2-propanediol, hydrate) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2), in development for treating type 2 diabetes mellitus (T2DM). It inhibits SGLT2, responsible for at least 90% of glucose reabsorption in the kidney.

EG1, a novel specific inhibitor of Pax2 transcription activation, targets the DNA binding domain and inhibits embryonic kidney development.

Galactose is a monosaccharide and hexose sugar widely present in most living cells, primarily absorbed into the bloodstream via SGLT1 and GLUT2 transporters and metabolised through the Leloir pathway. It inhibits alglucerase activity in monkey kidney CoS-1 cells, is a key component of cellular glycosylation, and plays a crucial role in neonatal neural development.

Galegine hydrochloride, a guanidine derivative derived from G. officinalis, plays a role in inducing weight loss in mice and has contributed to the development of biguanides, including metformin and phenformin. This compound stimulates AMPK activation in 3T3-L1 adipocytes, L6 myotubes, H4IIE rat hepatoma, and HEK293 human kidney cell lines. Additionally, galegine hydrochloride exhibits antibacterial properties, particularly demonstrating a minimum inhibitory concentration of 4 mg L against Staphylococcus aureus strains[1][2].

Glycerol is an important component of triglycerides (fats and oils) and phospholipids. It is widely used in the food industry as a sweetener, humectant, and in pharmaceutical formulations. Additionally, glycerol is used in sample preparation and gel formation for polyacrylamide gel electrophoresis and can be employed to induce acute kidney injury models.

RET-IN-9 is a potent inhibitor of RET, a single-channel transmembrane receptor tyrosine kinase involved in kidney and enteric nervous system development, as well as in maintaining homeostasis in the nervous, endocrine, hematopoietic, and male reproductive systems. RET-IN-9 is potentially useful in studying RET-related diseases, including non-small cell lung cancer and medullary thyroid cancer.

Modimelanotide is a melanocortinergic peptide drug derived from α-melanocyte-stimulating hormone (α-MSH) which was under development for the treatment of acute kidney injury. It acts as a non-selective melanocortin receptor agonist.

Kisspeptin-10, human TFA, is a potent vasoconstrictor and angiogenesis inhibitor that also suppresses tumor metastasis through its interaction with the receptor GPR54. It is crucial for embryonic kidney development and promotes osteoblast differentiation through NFATc4-mediated BMP2 expression via the Kisspeptin-10 GPR54 signaling pathway [1].

CK7 (a Cdk2 9 inhibitor) is crucial in synthesizing Nek1 inhibitors [BSc5231] and [BSc5367].

Kisspeptin-10, human TFA is a potent vasoconstrictor and angiogenesis inhibitor. Kisspeptin-10, human TFA acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression